Zevra Therapeutics (ZVRA): Rentabilitas dodolan miturut bathi resik

Zevra Therapeutics Inc - logo grafis emiten ZVRA

Zevra Therapeutics (ZVRA) demonstrates recession resilience through the commercialization of orphan drugs. The net margin per unit of revenue illustrates this stability, and this metric equals 50.70. Growth is based on the monopolization of the neurometabolic niche and IT patient support systems. Simultaneously, the company is implementing energy-efficient logistics and laboratory waste disposal to comply with ESG standards.

ZVRA: Margin bathi resik Zevra Corp 28.04.2023 - 20.11.2026

Rincian metrik keuangan lan pasar Zevra Corp (ZVRA)

- rega saham lan prakiraan rega para ahli:
Ringkesan analitik perusahaan:zevra.com - ZVRA
Produk dadi Kempharm

Analyzing the scale of Zevra Therapeutics (ZVRA) operations through the lens of average sales margins allows for a comparison of current operating efficiency against the company's historical trend. This indicator is calculated as the ratio of net income to total revenue, reflecting the profit share of every dollar of sales, which is critical for assessing a pharmaceutical business's ability to cover marketing costs and the risks of FDA approval delays.